Biohaven Ltd. (BHVN) – What Are Analysts Thinking About This Stock?

Biohaven Ltd. (NYSE:BHVN) has been given a consensus rating of “Moderate Buy” by the seventeen ratings firms that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, five have given a hold recommendation, eight have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $18.69.

Several brokerages have issued reports on BHVN. Citigroup reissued a “buy” rating on shares of Biohaven in a research note on Friday, September 18th. Morgan Stanley increased their price target on Biohaven from $18.00 to $19.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Biohaven in a research report on Thursday. TD Cowen reiterated a “buy” rating on shares of Biohaven in a research note on Wednesday, August 26th. Finally, Wall Street Zen upgraded shares of Biohaven from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th.

Hedge Funds Weigh In On Biohaven

Several institutional investors have recently made changes to their positions in BHVN. Janus Henderson Group PLC boosted its holdings in Biohaven by 1,145.9% during the 1st quarter. Janus Henderson Group PLC now owns 17,534,612 shares of the company’s stock worth $148,214,000 after acquiring an additional 16,127,247 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Biohaven in the 2nd quarter worth $196,574,000. Jupiter Topco LLC bought a new stake in shares of Biohaven in the 2nd quarter worth $127,852,000. Stempoint Capital LP purchased a new stake in shares of Biohaven in the first quarter valued at about $13,489,000. Finally, Bank of America Corp DE purchased a new stake in shares of Biohaven in the second quarter valued at about $21,990,000. Institutional investors and hedge funds own 88.78% of the company’s stock.

Biohaven Stock Down 2.6%

Shares of NYSE:BHVN opened at $11.77 on Thursday. The company has a market capitalization of $1.78 billion, a price-to-earnings ratio of -2.54 and a beta of 1.35. The company has a debt-to-equity ratio of 21.23, a current ratio of 4.73 and a quick ratio of 4.73. The business’s 50-day moving average is $13.94 and its 200-day moving average is $12.53. Biohaven has a 1 year low of $7.48 and a 1 year high of $18.57.

Biohaven (NYSE:BHVN) last announced its earnings results on Monday, August 10th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.15). Equities research analysts predict that Biohaven will post -3.33 earnings per share for the current year.

About Biohaven

Biohaven Ltd. (NYSE: BHVN) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for neurological and immunological disorders. The company uses proprietary drug-development platforms to pursue treatments for conditions with significant unmet medical needs, including migraine, epilepsy, obsessive-compulsive disorder and other central nervous system diseases.

Biohaven’s pipeline has included small-molecule and biologic candidates such as troriluzole, an investigational therapy being studied in several neurological disorders, and other programs targeting ion channels, glutamate signaling and immune pathways.